lsc-webmaster

Clinical evaluation of the potential of ILR201104 to treat COVID-19 related ARDS. Immune Regulation Ltd, a US and UK based clinical stage biotechnology company, today announced that it has entered into a Teaming Agreement with DynPort Vaccine Company LLC (DVC; a GDIT Company) to jointly evaluate the potential of Immune Regulation’s drug product ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.

Immune Regulation Ltd, a clinical stage biotech company, today announces the appointment of Jonathan Rigby as CEO and a member of the Board of Directors. Based in the U.S., Jonathan is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he became the CEO of

COVID-19 the overwhelming potential pathology with those at highest risk to COVID-19 infection is uncontrolled activation of the immune system to combat infection, particularly overactivation of neutrophils.  However, in the vulnerable, the action of these mediators lead to the destructive inflammation that can lead to overwhelming inflammation, leading to death.  This outcome could be a

Immune Regulation Limited (‘Immune Regulation’ or the ‘Company’) a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, publically presented exciting preclinical data on IRL201104 (formerly PIN201104 or ‘1104) for the first time at the annual American Thoracic Society (ATS) International Conference in Dallas, Texas, held on 17th-22nd May.

The ATS Annual Conference is one of the leading pulmonary care (including allergy/immunology) events of the year attracting over 14,000 leading healthcare professionals from around the world.

Immune Regulation Ltd. (‘Immune Regulation’ or the ‘Company’, formerly known as Peptinnovate), a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces positive results from a Phase 1 study of its lead compound IRL201104 (‘1104).

Study C1104-001 was a First Time in Human, randomised, double blind, placebo controlled, parallel group study in healthy volunteers and patients with asthma to assess the safety, tolerability and pharmacokinetics of single ascending and repeat doses of ‘1104.

Peptinnovate Ltd (‘Peptinnovate’ or the ‘Company’, a biotechnology company developing novel immune modulators for immunological and inflammatory diseases, announces that it has changed its corporate name from Peptinnovate to Immune Regulation with immediate effect. The new website for Immune Regulation is www.immuneregulation.com.

Richard Nagle, CEO of Immune Regulation, formerly Peptinnovate, commented:
“Re-branding the Company as Immune Regulation better reflects our expanding clinical pipeline of novel immuno-modulating therapies following Peptinnovate’s acquisition of Immune Regulation Ltd. and its lead molecule, IRL201805 earlier this year.

Immune Regulation Limited (‘Immune Regulation’ or the ‘Company’) a biopharmaceutical company developing “first in class” immune-resetting therapies for asthma and other inflammatory diseases, announces that Dr. Roly Foulkes, Chief Scientific Officer, took part in a panel discussion titled “What’s New in Autoimmune Disease?” at the BioTrinity 2019 conference in London on 1 May 2019.

Alongside leading industry peers from Cambridge Immunology Network, Eli Lilly, M Ventures and UCL, Dr Foulkes discussed the importance of immune system resetting, potential targets for autoimmune drug development, priority autoimmune diseases for research and what biotechnology companies working in this space need to succeed.